Proactive Investors - Run By Investors For Investors

ANGLE’s Novocellus starts EmbryoSure clinical trial

ANGLE's Novocellus business plans to recruit around 400 patients and the trial is scheduled for completion in mid-year 2013.  Product launch in the UK is anticipated in mid-year 2014.
ANGLE’s Novocellus starts EmbryoSure clinical trial

ANGLE (LON:AGL) said its 92 per cent held Novocellus business has started the clinical trial for the EmbryoSure product used in in-vitro fertilisation (IVF).

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the amended EmbryoSure trial and patient recruitment starts this week.

Novocellus plans to recruit around 400 patients and the trial is scheduled for completion in mid-year 2013.  Product launch in the UK is anticipated in mid-year 2014.

Four leading UK IVF clinics are participating in the trial, namely: IVF Hammersmith Ltd at Hammersmith Hospital; CARE Fertility in Manchester, the UK's largest independent provider of assisted conception cycles; The Leeds Centre for Reproductive Medicine (LCRM) and the Hewitt Centre for Reproductive Medicine at Liverpool Women's NHS Foundation Trust.

Novocellus has a partnership with Danish group ORIGIO, a supplier of specialised IVF products. ORIGIO has the right to license the EmbryoSure intellectual property in exchange for milestone payments and a royalty on future net sales.

The business secured a second patent for EmbryoSure in the US, extending the period during which Novocellus would receive royalties.

If the EmbryoSure trials are successful, the royalty potential for Novocellus if the product is adopted across ORIGIO's entire existing customer base is circa £25 million per annum.

The impact of the second Novocellus patent granting will potentially translate into additional cumulative royalty income of more than £150 million to Novocellus.

The science behind the product was developed by the University of York, and it tests the amino acid profile of the culture medium used to carry the fertilised egg.  

ANGLE believes EmbryoSure will identify with 95 per cent confidence which one of the embryos is likely to be a top quartile embryo. Currently there is no such means of identifying the best eggs.

Novocellus reckons EmbryoSure has the potential to increase pregnancy rates by a quarter and possibly by as much as 40 per cent.

ANGLE operates as a specialist medical technology company with products in cancer diagnostics and fetal health, and it also owns a specialist technology consultancy.

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”
April 18 2017
Iclaprim is one of the next-generation of antibiotics and it will be used, initially at least, to treat acute bacterial skin and skin structure infections
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use